These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15791469)

  • 21. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Targeted Therapy Influence Renal Surgery for Renal Cell Carcinoma.
    Greco F; Marchioni M; Esperto F; Papalia R; Schips L; Scarpa RM
    Curr Drug Targets; 2020; 21(15):1550-1557. PubMed ID: 32621715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive nephrectomy: past, present and future.
    Galazi M; Rodriguez-Vida A; Josephides E; Chau NM; Chowdhury S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):271-7. PubMed ID: 24392671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
    Vaishampayan UN
    Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Pantuck AJ; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of renal surgery in the era of targeted therapy: the urologist's perspective.
    Battaglia M; Lucarelli G
    Urologia; 2015; 82(3):137-8. PubMed ID: 25704789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-surgical targeted molecular therapy in renal cell carcinoma.
    Margulis V; Wood CG
    BJU Int; 2009 Jan; 103(2):150-3. PubMed ID: 19007359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of cytoreductive nephrectomy in renal cell carcinoma.
    Chiong E; Wood CG; Margulis V
    Future Oncol; 2009 Aug; 5(6):859-69. PubMed ID: 19663735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
    Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
    Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
    Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
    Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Healy KA; Marshall FF; Ogan K
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Doehn C; Jocham D
    Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Margulis V; Matin SF; Wood CG
    Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
    Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
    N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.